Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia-Reference-Cited by-同舟云学术

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

Published:2011-05-12 Issue:2 Volume:154 Page:223-228
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Treon Steven P.,Yang Guang,Hanzis Christine,Ioakimidis Leukothea,Verselis Sigitas J.,Fox Edward A.,Xu Lian,Hunter Zachary R.,Tseng Hsiuyi,Manning Robert J.,Patterson Christopher J.,Sheehy Patricia,Turnbull Barry

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2011.08726.x/fullpdf

Reference45 articles.

1. The relationship of Fcgamma RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus;Anolik;Arthritis and Rheumatism,2003

2. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene;Cartron;Blood,2002

3. Long term survival in Waldenstrom Macroglobulinaemia: 10 year follow-up of Southwest Oncology Group-directed intergroup trial S9003;Dhodapkar;Blood,2009

4. Treatment of Waldenstrom’s Macroglobulinaemia with rituximab: prognostic factors for response and progression;Dimopoulos;Leukemia and Lymphoma,2004

5. Predictive factors for response to rituximab in Waldenstrom’s Macroglobulinaemia;Dimopoulos;Clinical Lymphoma,2005

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of real-time quantitative PCR and two digital PCR platforms to detect copy number variation in FCGR3B;Journal of Immunological Methods;2024-03

2. Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia;Leukemia;2024-02-26

3. Waldenstrom Macroglobulinemia;Comprehensive Hematology and Stem Cell Research;2024

4. Ibrutinib and venetoclax as primary therapy in symptomatic treatment naïve Waldenström macroglobulinemia;Blood Journal;2023-10-27

5. Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia;2023-09-19